We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals

234 hedge funds and large institutions have $4.52B invested in Ionis Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 85 increasing their positions, 78 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

110% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 21

10% more funds holding

Funds holding: 213234 (+21)

10% more capital invested

Capital invested by funds: $4.13B → $4.52B (+$393M)

9% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 78

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

33% less call options, than puts

Call options by funds: $92.9M | Put options by funds: $140M

Holders
234
Holders Change
+21
Holders Change %
+9.86%
% of All Funds
6.76%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.12%
New
44
Increased
85
Reduced
78
Closed
21
Calls
$92.9M
Puts
$140M
Net Calls
-$46.6M
Net Calls Change
-$23.8M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$758M +$28.7M +592,014 +3%
Artisan Partners
2
Artisan Partners
Wisconsin
$379M -$97.6M -2,014,378 -19%
Vanguard Group
3
Vanguard Group
Pennsylvania
$336M +$5.06M +104,400 +1%
ClearBridge Investments
4
ClearBridge Investments
New York
$317M +$7.11M +146,601 +2%
BB
5
BB Biotech
Switzerland
$272M -$5.62M -116,022 -2%
WRF
6
Waddell & Reed Financial
Kansas
$230M +$27.8M +574,300 +12%
BFA
7
BlackRock Fund Advisors
California
$189M +$8.5M +175,355 +4%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$140M -$5.82M -120,158 -4%
BIT
9
BlackRock Institutional Trust
California
$135M +$1.92M +39,641 +1%
State Street
10
State Street
Massachusetts
$104M +$657K +13,556 +0.6%
Franklin Resources
11
Franklin Resources
California
$91.2M +$18.1M +373,329 +21%
PA
12
Pinnacle Associates
New York
$83.9M -$3.67M -75,705 -4%
Jennison Associates
13
Jennison Associates
New York
$82.8M +$396K +8,161 +0.4%
Northern Trust
14
Northern Trust
Illinois
$65.8M -$6.91M -142,509 -9%
CCI
15
Columbus Circle Investors
$62.6M +$45.5M +938,486 +184%
TAM
16
Tocqueville Asset Management
New York
$54.5M -$19.3M -398,181 -24%
AllianceBernstein
17
AllianceBernstein
Tennessee
$49.3M +$1.22M +25,076 +2%
American Century Companies
18
American Century Companies
Missouri
$48.4M +$48.1M +993,171 +781%
BA
19
BlackRock Advisors
Delaware
$39.1M +$3.22M +66,471 +8%
SAM
20
Sectoral Asset Management
Quebec, Canada
$38.1M -$16.5M -340,300 -28%
SI
21
Scout Investments
Missouri
$37.5M +$42M +867,252 New
Stifel Financial
22
Stifel Financial
Missouri
$36.7M +$41.2M +849,096 New
Norges Bank
23
Norges Bank
Norway
$32.5M
ACM
24
Apex Capital Management
Ohio
$30.9M -$2.06M -42,593 -6%
EAM
25
Eagle Asset Management
Florida
$29.7M -$30.7M -632,548 -48%

IONS Hedge Fund Activity: Q1 2014 in Review

234 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2014, worth a combined $4.52B — up 9.5% from $4.13B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new IONS positions and 21 closed out — a net gain of 23 holders — while 85 added to existing stakes and 78 trimmed.

The largest buyer was American Century Companies, adding an estimated $48.1M. The largest seller was Artisan Partners, cutting an estimated $97.6M.

  • 234 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2014, up from 213 in Q4 2013.
  • Funds reported $4.52B of Ionis Pharmaceuticals stock for Q1 2014, up 9.5% quarter-over-quarter.
  • 44 funds opened new Ionis Pharmaceuticals positions in Q1 2014 and 21 closed out, a net change of +23 holders.
  • The largest Ionis Pharmaceuticals buyer in Q1 2014 was American Century Companies, an estimated $48.1M added.
  • The largest Ionis Pharmaceuticals seller in Q1 2014 was Artisan Partners, an estimated $97.6M sold.

Based on aggregated 13F filings for Q1 2014.